Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) closed the day trading at $369.96 down -0.26% from the previous closing price of $370.91. In other words, the price has decreased by -$0.26 from its previous closing price. On the day, 1.63 million shares were traded. ALNY stock price reached its highest trading level at $376.88 during the session, while it also had its lowest trading level at $366.95.
Ratios:
For a better understanding of ALNY, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 17.94 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 220.80. For the most recent quarter (mrq), Quick Ratio is recorded 2.49 and its Current Ratio is at 2.54. In the meantime, Its Debt-to-Equity ratio is 11.86 whereas as Long-Term Debt/Eq ratio is at 11.17.
Oppenheimer Upgraded its Perform to Outperform on August 04, 2025, while the target price for the stock was maintained at $490.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jan 13 ’26 when Fitzgerald Kevin Joseph bought 2,290 shares for $369.10 per share.
Fitzgerald Kevin Joseph sold 12,128 shares of ALNY for $5,483,990 on Nov 17 ’25. The CSO & EVP, Head of Research now owns 21,264 shares after completing the transaction at $452.18 per share. On Nov 17 ’25, another insider, Fitzgerald Kevin Joseph, who serves as the Officer of the company, bought 12,128 shares for $449.00 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ALNY now has a Market Capitalization of 48876826624 and an Enterprise Value of 48925511680. As of this moment, Alnylam’s Price-to-Earnings (P/E) ratio for their current fiscal year is 1538.94, and their Forward P/E ratio for the next fiscal year is 46.57. For the stock, the TTM Price-to-Sale (P/S) ratio is 15.23 while its Price-to-Book (P/B) ratio in mrq is 208.46. Its current Enterprise Value per Revenue stands at 15.241 whereas that against EBITDA is 152.406.
Stock Price History:
The Beta on a monthly basis for ALNY is 0.34, which has changed by 0.4776702 over the last 52 weeks, in comparison to a change of 0.1726681 over the same period for the S&P500. Over the past 52 weeks, ALNY has reached a high of $495.55, while it has fallen to a 52-week low of $205.87. The 50-Day Moving Average of the stock is -12.83%, while the 200-Day Moving Average is calculated to be -1.66%.
Shares Statistics:
Over the past 3-months, ALNY traded about 1.33M shares per day on average, while over the past 10 days, ALNY traded about 1342440 shares per day. A total of 131.79M shares are outstanding, with a floating share count of 129.79M. Insiders hold about 1.76% of the company’s shares, while institutions hold 99.56% stake in the company. Shares short for ALNY as of 1767139200 were 5532159 with a Short Ratio of 4.15, compared to 1764288000 on 3960190. Therefore, it implies a Short% of Shares Outstanding of 5532159 and a Short% of Float of 5.510000000000001.
Earnings Estimates
At present, 12.0 analysts are actively evaluating the performance of Alnylam Pharmaceuticals Inc (ALNY) in the stock market.The consensus estimate for the next quarter is $2.49, with high estimates of $3.32 and low estimates of $1.82.
Analysts are recommending an EPS of between $5.99 and $2.57 for the fiscal current year, implying an average EPS of $4.8. EPS for the following year is $11.29, with 13.0 analysts recommending between $18.05 and $5.55.
Revenue Estimates
19 analysts predict $1.16B in revenue. The current quarter. It ranges from a high estimate of $1.61B to a low estimate of $1.07B. As of. The current estimate, Alnylam Pharmaceuticals Inc’s year-ago sales were $593.17MFor the next quarter, 19 analysts are estimating revenue of $1.25B. There is a high estimate of $1.45B for the next quarter, whereas the lowest estimate is $1.11B.
A total of 24 analysts have provided revenue estimates for ALNY’s current fiscal year. The highest revenue estimate was $4.23B, while the lowest revenue estimate was $3.68B, resulting in an average revenue estimate of $3.78B. In the same quarter a year ago, actual revenue was $2.25BBased on 25 analysts’ estimates, the company’s revenue will be $5.48B in the next fiscal year. The high estimate is $7.36B and the low estimate is $4.34B.
